The purpose of this study was to evaluate the therapeutic efficacy and limitations of α-
particle-emitting radiolabeled compounds by means of 2-dimensional histological images …

Bioconjugates used in internal radiotherapy exhibit heterogeneous distributions in organs
and tumors, implying a risk of nonuniform dose distribution in therapeutic applications using …

Because of the short path length in tissues (100 m) and the high linear energy transfer (100
keV/m),-particle therapy offers the potential for specific tumor cell killing with a low level of …

Abstract Kennel, SJ, Mirzadeh, S., Eckelman, WC, Waldmann, TA, Garmestani, K., Yordanov,
AT, Stabin, MG and Brechbiel, MW Vascular-Targeted Radioimmunotherapy with the Alpha …

With the increasing availability of alpha emitters, targeted α-particle therapy has emerged as
a solution of choice to treat haematological cancers and micrometastatic and minimal …

Objectives To demonstrate the feasibility of 90 Y-PET imaging for biodistribution assessment
after selective internal radiotherapy treatments with 90 Y-microspheres, comparing the …

α-particle radiotherapy has already been shown to be impervious to most resistance
mechanisms. However, in established (ie, large, vascularized) soft-tissue lesions, the …

Purpose: Alpha‐emitting radionuclides exhibit a potential advantage for cancer treatments
because they release large amounts of ionizing energy over a few cell diameters (50–80 …

Radiopharmaceutical therapy (RPT) involves the use of radionuclides that are either
conjugated to tumor-targeting agents (eg, nanoscale constructs, antibodies, peptides, and …

An in vivo lung tumor model system for radioimmunotherapy of lung metastases was used to
test the relative effectiveness of the vascular-targeted β-particle emitter 90Y, and α-particle …